FOLH1 and posterior cortical atrophy: Presently, a phase II study is testing 99mTc-MIP-1404 PSMA inhibitor in patients with high-risk PCa scheduled for radical prostatectomy (RP) surgery including extended pelvic lymph node (LN) dissection compared to histopathology (NCT01667536).